Skip to main content

Table 1 Baseline characteristics and pulse wave analysis

From: Augmentation index is associated with coronary revascularization in patients with high Framingham risk scores: a hospital-based observational study

  PCI group Non-PCI group p
  n = 73 (%) n = 159 (%)  
Male 50 (68.5) 97 (61.0) 0.306
Age (years) 64.8 ± 10.3 59.6 ± 13.1 0.001
Height (cm) 163.8 ± 7.7 163.0 ± 8.5 0.486
Body weight (Kg) 66.9 ± 11.4 68.2 ± 11.4 0.442
Body mass index (kg/m2) 24.8 ± 3.5 25.6 ± 3.2 0.085
Brachial systolic pressure (mmHg) 148.9 ± 22.4 144.1 ± 22.6 0.135
Brachial diastolic pressure (mmHg) 87.0 ± 11.0 85.1 ± 10.5 0.203
Brachial pulse pressure (mmHg) 61.8 ± 17.6 58.7 ± 17.6 0.216
CVD risk points 18.6 ± 4.0 14.9 ± 5.4 <0.001*
10-year estimate of CVD risk (%) 25.3 ± 6.5 18.8 ± 10.2 <0.001*
Diabetes 20 (27.4) 33 (20.8) 0.312
Hypertension 53 (72.6) 78 (49.1) 0.001
Hyperlipidemia 34 (46.6) 46 (28.9) 0.011
Total cholesterol (mg/dL) 181.1 ± 45.6 185.9 ± 54.0 0.513
HDL cholesterol (mg/dL) 41.0 ± 11.2 46.0 ± 12.3 0.002*
Smoking 24 (32.9) 40 (25.2) 0.268
Left ventricular ejection fraction (n = 111) 59.0 ± 14.5 65.3 ± 10.1 0.036
Central pulse pressure (mmHg) 53.4 ± 17.1 49.4 ± 18.0 0.110
Augmented pressure (mmHg) 20.3 ± 9.5 16.9 ± 8.8 0.009
Augmentation index (%) 36.5 ± 9.3 32.5 ± 10.0 0.004
Augmentation index @75 (%) 31.6 ± 8.5 27.2 ± 9.0 0.006**
  1. CVD cardiovascular disease, HDL high-density lipoprotein, PCI percutaneous coronary intervention, Data are expressed as means ± standard deviation or numbers (percentage); chi-square test or Wilcoxon two-sample test (or Mann–Whitney U test)
  2. *p value for comparison between the PCI (n = 70) and non-PCI (n = 146); p < 0.05 considered significant
  3. **ANCOVA test: adjusting for ejection fraction (n = 111)